Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.43 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611442 | 0.90 | KDM4E (0.55) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL17258384 | 0.89 | KDM4E (0.53) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL7770340 | 0.82 | AHR (0.49) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL5387510 | 0.82 | AHR (0.49) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2956687 | 0.82 | AHR (0.49) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL5160219 | 0.82 | KDM4E (0.64) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL31127018 | 0.81 | AHR (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL7931837 | 0.80 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL9323548 | 0.78 | AHR (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL3815890 | 0.78 | BRD4 (0.50) | KDM4EAHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-3774767-B1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12152016-B2 | Aryl hydrocarbon receptor modulators and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| EP-1246802-A1 | 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | Dow Agrosciences LLC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1165501-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001051468-A1 | 4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6197770-B1 | ENZYME INHIBITORS; ANTIARTHRITIC AGENTS; BONE DISORDERS | THE PROCTER & GAMBLE CO. | 2001-03-06 | — | — | US | disclosed |
| WO-2000051975-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | KDM4E 3627/4885ALOX15 1537/4885TSHR 1858/4885 |
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | KDM4E 3458/4885ALOX15 2564/4885TSHR 1670/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALOX15 3105/4885TSHR 3319/4885 |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | KDM4E 1261/4885ALOX15 4297/4885TSHR 4039/4885 |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALOX15 3105/4885TSHR 3319/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885ALOX15 3105/4885TSHR 3319/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALOX15 3885/4885TSHR 3990/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | KDM4E 3627/4885ALOX15 1537/4885TSHR 1858/4885 |
| US-12152016-B2 | Aryl hydrocarbon receptor modulators and uses thereof | AHR, ARNT, NR4A1 | KDM4E 2079/4885ALOX15 1004/4885TSHR 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.